BDX•benzinga•
Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years
Summary
Becton Dickinson receives multiple downgrades as analysts cite weakening organic growth and trimmed price targets following a Q2 update.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 2, 2025 by benzinga